SCHEMBL514939

SCHEMBL514939

[CH2]C(=O)c1cccc(Br)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.69
ALDH1A1 P00352 3/20 0.55
TP53 P04637 1/20 0.55
C1S P09871 1/20 0.52
HPGD P15428 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
KDM4E B2RXH2 1/20 0.47
MAPK1 P28482 1/20 0.47
GAA P10253 2/20 0.47
NPC1 O15118 2/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
MAPT P10636 2/20 0.45
BCHE P06276 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163949 0.82 PARP1 (1.00) PARP1ALDH1A1TP53C1SHPGD
SCHEMBL16803128 0.82 PARP1 (1.00) PARP1ALDH1A1TP53C1SHPGD
SCHEMBL241785 0.81 PARP1 (0.68) PARP1ALDH1A1TP53C1SHPGD
SCHEMBL30153175 0.81 PARP1 (0.68) PARP1ALDH1A1TP53C1SHPGD
SCHEMBL6670439 0.81 PARP1 (0.68) PARP1ALDH1A1TP53C1SHPGD
Hydrochloric Acid SCHEMBL4376137 0.80 PARP1 (0.96) PARP1ALDH1A1TP53C1SHPGD
Hydrochloric Acid SCHEMBL5319538 0.80 PARP1 (0.96) PARP1ALDH1A1TP53C1SHPGD
SCHEMBL180430 0.79 PARP1 (0.65) PARP1ALDH1A1TP53C1SHPGD
SCHEMBL8681033 0.79 PARP1 (0.65) PARP1ALDH1A1TP53C1SHPGD
SCHEMBL5023 0.79 PARP1 (0.65) PARP1ALDH1A1TP53C1SHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109053847-B 17 β -imidazolidinyl bromide-dehydroepiandrostane derivative and preparation method and application thereof 云南大学 2020-05-19 CN claimed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
EP-3313832-B1 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2021-02-24 EP disclosed
CN-109053847-B 17 β -imidazolidinyl bromide-dehydroepiandrostane derivative and preparation method and application thereof 云南大学 2020-05-19 CN disclosed
US-10544130-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-01-28 US disclosed
US-20190144432-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-05-16 US disclosed
US-10221163-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-05 US disclosed
US-20180244656-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-08-30 US disclosed
EP-3313832-A1 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-05-02 EP disclosed
WO-2016210215-A1 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 WO disclosed
US-4451481-A ANTICHOLESTEROL AGENTS SANKYO COMPANY LIMITED (JP) 1984-05-29 US disclosed
US-4447626-A TREATMENT OF HYPERCHOLESTEROLEMIA SANKYO COMPANY LIMITED (JP) 1984-05-08 US disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 US disclosed
EP-0076601-A1 Octahydronaphthalene derivatives and their preparation SANKYO COMPANY LIMITED (JP) 1983-04-13 EP disclosed
EP-0074222-A1 MB-530B derivatives, their preparation and pharmaceutical compositions containing them SANKYO COMPANY LIMITED (JP) 1983-03-16 EP disclosed
EP-0070649-A2 ML-236B Derivatives, a process for their preparation and pharmaceutical compositions containing them SANKYO COMPANY LIMITED (JP) 1983-01-26 EP disclosed
EP-0065835-A1 M-4 and iso M-4 derivatives, their preparation and compositions containing them SANKYO COMPANY LIMITED (JP) 1982-12-01 EP disclosed
EP-0065843-A1 New M-4 and iso M-4 derivatives, their preparation and compositions containing them SANKYO COMPANY LIMITED (JP) 1982-12-01 EP disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 US disclosed
US-4137322-A ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents SANKYO COMPANY LIMITED (JP) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544130-B2 Metallo-beta-lactamase inhibitors MLX, ZFX, MMP12 PARP1 1761/4885ALDH1A1 277/4885TP53 4403/4885
US-10221163-B2 Metallo-beta-lactamase inhibitors MLX, ZFX, MMP12 PARP1 1810/4885ALDH1A1 259/4885TP53 4474/4885
US-20190144432-A1 METALLO-BETA-LACTAMASE INHIBITORS MLX, ZFX, MMP12 PARP1 1761/4885ALDH1A1 277/4885TP53 4403/4885
US-20180244656-A1 METALLO-BETA-LACTAMASE INHIBITORS MLX, ZFX, MMP12 PARP1 1810/4885ALDH1A1 259/4885TP53 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.